During the early years, Huard and Andrea Doria et al. described that high-dose dexamethasone treatment was beneficial for the treatment of myasthenia gravis by significantly reducing B-cell activating factor (BAFF) and its mRNA in circulating blood (Huard et al. 2001), (Zen et al. 2011). The gene discussed is TNFSF13B; the disease is myasthenia gravis.